Medical Research Programs and Clinical Trials

Group 430

PIR’s focus and goal are not only to treat individual community members and their families but also to establish best practices, develop comprehensive training programs, and expand safe and effective treatment with these innovative therapies.

PIR’s programs will focus non-exclusively on therapies, treatment, and licensing for clinical trials on cannabis and psychedelics for trauma, addiction, PTSD, depression, and co-occurring mental health conditions.

Promises Innovative Recovery is pleased to offer our community members and partners access

to approved clinical trials and observational research opportunities. Built on a research framework, PIR is setting the standard for clinical trial management and conduct in the areas such as mental health (depression, anxiety, PTSD, addiction), opioid harm reduction, concussion/Traumatic Brain Injury (prevention and recovery), chronic pain and Central Nervous System (CNS) disorders.
Group 431

Because of the prohibition and perceived risk associated with cannabis and psychedelics, most research has been focused on using these treatments at the end of life.

It’s not uncommon to give cancer patients cannabis at the end of life for pain management, to address appetite concerns, and increase better feeling states.

While that’s valuable, PIR aims to use these therapies to help individuals enjoy their lives

instead of waiting until their end to access these revolutionary treatments. All research completed at PIR will include real-time data to prove these innovative medicines’ safety, efficacy, dosage, and protocols. In turn, this will assist individuals, institutions, and suppliers to make them more readily available in the marketplace as preventative measures.

Group 678
Group 433

PIR supports government and medical communities

by producing real-time data during community member visits. Building an onsite Phase I-IV clinical trial building gives PIR the ability to gather research data and supporting evidence of cutting-edge protocols in the plant-based psychedelic industry.
This data will be collected and provided for evaluation by the FDA to create the standard in care using these new innovative therapies and medicines, allowing us to expand to the USA, Canada, and globally—permitting us to treat millions of community members worldwide.
To inquire about upcoming research opportunities and if you are a study sponsor or interested in adding PIR as your study site, reach out.
Contact Us
Group 434
Mask Group 19 tinified
Mask Group 20
Mask Group 17 v2 tinified
Mask Group 21 tinified
Mask Group 18 tinified
Mask Group 22
logo

Unlike any other outpatient treatment center, we have developed a comprehensive and results-driven wellness and healing program with proven methods and end-to-end support for lifelong recovery through plant-based medicines.

Stay Connected
  • promiseskept@promisesinnovativerecovery.com